Pharmacology in Ukraine: September 2025 — new standards, accessibility, investments

In September 2025, Ukraine’s pharmaceutical industry reached several important milestones: from strengthening control and raising standards to truly expanding access to medicines. These steps are not just operational changes, but signals of industry renewal. Here’s what you need to know.

🛡 Creation of the National Drug Verification Organization

On September 18, 2025, a meeting of the constituent assembly was held, which laid the foundation for the creation of the National Organization for the Verification of Medicinal Products (NOVL) in Ukraine.

This is a key victory: a concept that has been discussed for a long time is being implemented. Through this organization, medicines will be labeled with a two-dimensional code, tracked in the supply chain, and the risk of counterfeiting will be reduced.

Why is this important:

• Why is this important:
• Manufacturers get the expected transparency and manufacturer-to-patient lead time.
• The sphere is becoming closer to European standards — a “trust” trigger.

💊 Expansion of the Affordable Medicines Program

As of September 30, 2025, the Ministry of Health of Ukraine has expanded the “Affordable Medicines” program, adding 85 new drugs. The list includes drugs for pregnant women and mothers, thyroid, glaucoma, childhood diseases, cardiovascular, respiratory, metabolic, and neuropsychiatric disorders.

What does this mean:

• Millions of Ukrainians will have the opportunity to receive treatment more affordable or for free.
• Therapy becomes more socially inclusive — the trigger is “justice.”
• Pharmacies, pharmacists, manufacturers — all in the system of changes.

📊 Webinar on new drug price regulation

On September 25, a webinar was held entitled “180 Days of New Regulation of Drug Prices. Results, Prospects, and Practical Recommendations.” The following topics were discussed: impact on the market, problems with filling out the National Price Catalog, calculation of the maximum wholesale selling price, and the difference between catalog prices and registration prices.

Main alarm signals:

• Manufacturers face administrative burdens.
• Some drugs may be delayed in registration or unavailable.
• The trigger “risk” is for pharmaceutical companies, pharmacies, and patients.

🌍 Ukrainedeyus and European integration: production and legislation strategy

On September 18, the Chairman of the Verkhovna Rada Committee on Health Care, Mykhailo Radutsky, emphasized that when adapting the Critical Medicines Act to Ukrainian legislation, Ukraine must take into account its own production potential of active pharmaceutical ingredients (API).

This is strategically important: Ukrainian pharma can become a player in the European market.

Key points:

• Domestic API production is a chance for economic sustainability.
• Legislation is being integrated into the European standard — the “innovation” trigger.
• Partnerships with the EU are an opportunity for development.

Conclusions

September 2025 is a month of transformations, not just news. Ukrainian pharmaceutical system:

• Sets standards for control and verification.
• Works on the availability of medicines for citizens.
• Rethinks pricing policy and regulation.
• Strategically entering the international production arena.

Those who work in the pharmaceutical sector — from manufacturers to pharmacists — now have the chance to be not just participants, but co-authors of change.